We thank Wagner and Gittard[@bib1] for the opportunity to clarify our statement about known adverse events associated with hemostatic powder. Our *VideoGIE* abstract details the step-by-step use of hemostatic powder highlighting a case of a bleeding GI stromal tumor recalcitrant to other endoscopic hemostatic techniques, successfully bridged to definitive surgical therapy.[@bib2] The commenters are correct in stating that colonic obstruction has not been reported for the device used in the video (Hemospray; Cook, Winston-Salem, NC, USA).

Bowel obstruction has been reported with other surgical hemostatic matrices,[@bib3] and we, therefore, believe it remains a theoretic risk to consider in the treatment of patients who have recently undergone hemostatic powder treatment. To mitigate this risk, the company recommends limiting the number of devices to 3, or 60 grams of bentonite powder in total, within a single session. It is worth mentioning that 1 study of the device, sometimes with the use of doses more than twice the currently recommended dose, did not report any occurrence of bowel obstruction.[@bib4]

As we previously mentioned, biliary obstruction and perforation are adverse events previously reported with the use of hemostatic powder.[@bib5], [@bib6], [@bib7], [@bib8] As such, we stand by our warning for the theoretic risk of cholangitis, particularly if hemostatic powder is used in or near the biliary orifice, and would advise caution when considering use of the device in these areas.
